New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
Date Published:
May 19, 2009 Price:
$5700 Source:
Datamonitor With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.
Scope
Overview of ongoing trends affecting R&D and how these will shape Pharma in the future
R&D Insight from Big Pharma industry executives
Analysis into Pharma's evolving R&D portfolio between 2006 and 2009, in addition to examination of pipeline M&A and collaborative deals
Case studies of innovative strategies used to maximize R&D productivity
Highlights
GlaxoSmithKline, Pfizer and AstraZeneca have the largest preclinical and clinical drug pipelines, each with approximately 200 candidates in development as of March 2009. In terms of volume growth Genentech's pipeline grew the most in terms of percentage points, almost doubling (up 95%).
Over the period 200609, the average growth per therapy area was 9.4%. In terms of percentage points, the therapy area experiencing the largest growth in pipeline candidates was ophthalmology, while cardiovascular pipelines saw the largest decline, indicative of Pharma's shift towards niche markets and personalized medicines.
The number of pipeline deals made during 200608 have steadily declined. However, with Biotech finding it hard to fund R&D at present, and with many companies going bankrupt, this will affect Big Pharma in the longer term, which is increasingly downsizing internal research becoming ever reliant on external sources.
Reasons to Purchase
Identify R&D trends in today's pharmaceutical market, and how these affect productivity and return on investment
Understand how a diverse range of strategies can improve R&D productivity and output, and identify how these can best be implemented
Gain insight into how to optimize R&D processes and increase the chance of clinical, and ultimately commercial success
More Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
